Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations

Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2001, Pages 1059-1071

  Podder, H ^a   Stepkowski, S M ^a   Napoli, K L ^a   Clark, J ^a   Verani, R R ^a   Chou, T C ^a   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; GLOMERULUS FILTRATION RATE; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; LIVER; MALE; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

EID: 0035042276     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
2. Cyclosporine
3. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters
4. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
5. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients
6. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
7. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
8. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
9. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. The RAPAMUNE Global Study Group
10. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function
11. The pathophysiology of Sandimmune (cyclosporine) in man and animals
12. Involvement of reactive oxygen species in kidney damage
13. Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity
14. In vivo expression of transforming growth factor-beta1 in humans: Stimulation by cyclosporine
15. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells
16. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension
17. Apoptosis and necrosis: Mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line
18. Cyclosporine A induces apoptosis in murine tubular epithelial cells: Role of caspases
19. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
20. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat
21. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat
22. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model
23. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
24. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat
25. Renal effects of rapamycin in the spontaneously hypertensive rat
26. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
27. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions
28. Iohexol clearance is an accurate and reliable measure of glomerular filtration rate in rats
29. Plasma clearance of non-radioactive iohexol as a measure of glomerular filtration rate
30. Tissue distribution, disposition, and metabolism of cyclosporine in rats
31. Metabolism of cyclosporine
32. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines
33. Applications of statistics in clinical chemistry. A critical evaluation of regression lines
34. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood
35. An appropriate statistical approach for the comparison of FPIA to HPLC for determination of cyclosporine concentrations in animal tissues
36. Routine clinical monitoring of sirolimus (rapamycin) whole blood concentrations by HPLC with ultraviolet detection
37. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations
38. A rigorous approach to the diagnosis of immunosuppressive synergy combination therapies
39. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
40. Influence of rat strain on rapamycin's kidney effects
41. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
42. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet
43. Correlation of pre-transplant test dose cyclosporine pharmacokinetic profiles and post-transplant sirolimus disposition in renal transplant recipients
44. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
45. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase
46. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo
47. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
48. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
49. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)